Home Tags Rubius Therapeutics

Tag: Rubius Therapeutics

RUBIUS THERAPEUTICS reported a loss of $47 million in the third quarter.

Rubius Therapeutics posts $47M loss in Q3 on increase in R&D...

CAMBRIDGE, Mass. - Rubius Therapeutics Inc. reported a loss of $47 million in the third quarter, or 59 cents per diluted share, the company...
RUBIUS THERAPEUTICS reported a loss of $39.4 million in the second quarter of 2019. The company has yet to record revenue..4 million in the second quarter of 2019, The company is yet to have revenue.

Rubius reports $39.4M loss in Q2, heralds progress

PROVIDENCE – Rubius Therapeutics Inc. reported on Tuesday a loss of $39.4 million in the second quarter of 2019, or 50 cents per diluted...
BROADENED MISSION: Carol Malysz, executive director of Providence-based biotechnology trade association RI BIO, said the group has broadened its focus. Previously known as MedMates, this year the company changed its name and approach to promote the entire biotech industry.
 / PBN PHOTO/MICHAEL SALERNO

Ocean State starting to see growth in biotech industry

RI BIO, a Providence-based biotechnology trade association, is on a mission to put Rhode Island on the biotech industry’s map. Despite the state having...

Rubius announces 3 new patents for cellular-therapy program

PROVIDENCE – Rubius Therapeutics, a Cambridge, Mass.-based biotech firm that develops and genetically engineers red blood cells for use in medications for rare diseases,...
RUBIUS THERAPEUTICS reported a $32.6 million loss in the first quarter of 2019.

Rubius Therapeutics reports $32.6M loss in Q1

SMITHFIELD – Rubius Therapeutics Inc. reported a net loss of $32.6 million in the first quarter of 2019, or 42 cents per diluted share,...

Rubius appoints Holles to board, Whitehead as SVP, chief quality officer

PROVIDENCE – Rubius Therapeutics Inc. has appointed Natalie Holles to its board of directors and Greg Whitehead as senior vice president and chief quality...

Rubius Therapeutics added to Nasdaq biotechnology index

SMITHFIELD – Biotechnology firm Rubius Therapeutics Inc. was added to the Nasdaq biotechnology index on Dec. 24. The company, based in Cambridge, Mass., but building...
RUBIUS THERAPEUTICS reported a $26.4 million loss for the third quarter. The company does not yet generate revenue.

Rubius reports $26.4M loss for Q3

PROVIDENCE – Cambridge, Mass.-headquartered Rubius Therapeutics Inc. announced a $26.4 million net loss for the third quarter of 2018 Tuesday. The company reported an...
PBN PHOTO/MIKE SKORSKI

Most-read stories on PBN.com, July 2018

1. 2018 40 Under Forty winners feted at Aldrich Mansion POSTED ONLINE: JULY 20. A record crowd of 475 took the occasion of a...

Rubius Therapeutics enters agreement to buy former Alexion site in Smithfield

SMITHFIELD – Rubius Therapeutics Inc., the Cambridge, Mass.-based company recently approved by the R.I. Commerce Corp. for up to $9 million in incentives to...
- Featured Event -

Latest News